Local heat plus 3% hydrogen peroxide for stubborn viral warts
Randomized Single-blind Parallel Controlled Clinical Trial of Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts
This will try a combination of local heat and topical 3% hydrogen peroxide on people whose viral warts have not cleared after at least two prior treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Sex | All |
| Sponsor | First Hospital of China Medical University Academic / other |
| Locations | 2 sites (Shenyang, Liaoning and 1 other locations) |
| Trial ID | NCT07565350 on ClinicalTrials.gov |
What this trial studies
This interventional program combines infrared local hyperthermia (about 44°C ± 2°C for 30 minutes per session) with topical 3% hydrogen peroxide applied to refractory viral warts. Participants are those with a disease course of two years or longer who have failed at least two prior treatments such as topical agents, cryotherapy, or laser. Treatments are delivered at the hospital site using a commercial infrared device and topical applications, with clinical follow-up to document wart clearance and recurrence. Safety exclusions include allergy to heat or hydrogen peroxide and inability to complete follow-up.
Who should consider this trial
Good fit: Ideal candidates are people with viral warts lasting two or more years who have not responded to at least two prior treatment methods and who can consent and attend follow-up visits.
Not a fit: People allergic to local hyperthermia or hydrogen peroxide, those with serious comorbid illnesses that preclude participation, or those unable to attend scheduled treatments and follow-up are unlikely to benefit.
Why it matters
Potential benefit: If successful, the approach could clear persistent warts and lower recurrence using a noninvasive, low-cost combination therapy.
How similar studies have performed: Previous work shows thermotherapy can stimulate local immune responses and help clear warts, while topical hydrogen peroxide has supportive tissue-level effects, but the specific combined approach has limited prior clinical data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- 1: Patients with a disease course of ≥2 years who have failed to respond to ≥2 treatment methods (such as topical ointments, cryotherapy, laser therapy, etc.) 2: The subject or their legal guardian is able to understand and sign the informed consent form/agree to participate in the study. Exclusion Criteria: * 1: The subject or their legal guardian is unable to understand and refuses to sign the informed consent form / refuses to participate in the study 2: Individuals allergic to local hyperthermia or hydrogen peroxide; 3: Subjects with tumors or other serious diseases are unable to complete this clinical study; 4: Due to personal or other objective reasons, it is not possible to ensure timely treatment and follow-up.
Where this trial is running
Shenyang, Liaoning and 1 other locations
- Infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) — Shenyang, Liaoning, China (Recruiting)
- Infrared hyperthermia device (Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Xinghua Gao
- Email: gaobarry@hotmail.com
- Phone: 024-83282524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.